These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33388949)

  • 21. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
    Giovinazzo H; Kumar P; Sheikh A; Brooks KM; Ivanovic M; Walsh M; Caron WP; Kowalsky RJ; Song G; Whitlow A; Clarke-Pearson DL; Brewster WR; Van Le L; Zamboni BA; Bae-Jump V; Gehrig PA; Zamboni WC
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):565-73. PubMed ID: 26822231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
    Chambers LM; Pendlebury A; Rose PG; Yao M; DeBernardo R
    Gynecol Oncol; 2020 Aug; 158(2):309-315. PubMed ID: 32499072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition)].
    Breast Cancer Group, Chinese Association for Clinical Oncologist (CACO)
    Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):617-623. PubMed ID: 32867451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies.
    Kesterson JP; Odunsi K; Lele S
    Chemotherapy; 2010; 56(2):108-11. PubMed ID: 20407236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study.
    Zhao Y; Su W; Liang G; Shan X; Ma W; Tang D; Li L; Niu X; Zhao S; Zhang Q; Zhao W
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):63. PubMed ID: 34696815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegylated Liposomal Doxorubicin Causes Kidney-limited Thrombotic Microangiopathy.
    Glezerman I; Salvatore S; Tap W; Kelly C; Brauer Ornelas CM; Shaikh A
    Am J Kidney Dis; 2024 Apr; 83(4):549-553. PubMed ID: 37839689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.
    Herzog TJ; Kutarska E; Bidzińsk M; Symanowski J; Nguyen B; Rangwala RA; Naumann RW
    Int J Gynecol Cancer; 2016 Nov; 26(9):1580-1585. PubMed ID: 27654255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.
    Mayer C; Brucker J; Schuetz F; Domschke C; Bechstein S; Heil J; Golatta M; Wallwiener M; Sohn C; Schneeweiss A; Rom J
    Arch Gynecol Obstet; 2016 Jul; 294(1):123-9. PubMed ID: 26498757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view.
    Blaha M; Martinkova J; Lanska M; Filip S; Malakova J; Kubecek O; Bezouska J; Spacek J
    Atheroscler Suppl; 2017 Nov; 30():286-293. PubMed ID: 29096853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study.
    Yang FO; Hsu NC; Moi SH; Lu YC; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):198-203. PubMed ID: 29045014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.
    Bun S; Yunokawa M; Tamaki Y; Shimomura A; Shimoi T; Kodaira M; Shimizu C; Yonemori K; Fujiwara Y; Makino Y; Terakado H; Tamura K
    Support Care Cancer; 2018 Jul; 26(7):2161-2166. PubMed ID: 29372396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Necessity of routine cardiac evaluation in patients receiving pegylated liposomal doxorubicin for gynecologic cancer.
    Dioun SM; Vilardo N; Goldberg GL; Gressel GM
    Gynecol Oncol; 2019 Nov; 155(2):301-304. PubMed ID: 31575390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.
    Constantinidou A; Jones RL; Scurr M; Al-Muderis O; Judson I
    Eur J Cancer; 2009 Nov; 45(17):2930-4. PubMed ID: 19767198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure.
    Savani M; Murugan P; Skubitz KM
    Clin Sarcoma Res; 2019; 9():1. PubMed ID: 30651969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
    Sparano JA; Makhson AN; Semiglazov VF; Tjulandin SA; Balashova OI; Bondarenko IN; Bogdanova NV; Manikhas GM; Oliynychenko GP; Chatikhine VA; Zhuang SH; Xiu L; Yuan Z; Rackoff WR
    J Clin Oncol; 2009 Sep; 27(27):4522-9. PubMed ID: 19687336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucocutaneous toxicity induced by pegylated liposomal doxorubicin: a single-institution, retrospective case series.
    Vaccaro M; Santarpia M; Calapai G; Mannucci C; Borgia F; Altavilla G; Cannavò SP
    Br J Dermatol; 2017 Feb; 176(2):507-509. PubMed ID: 27291307
    [No Abstract]   [Full Text] [Related]  

  • 39. Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin.
    Hu X; Dong M; Liang X; Liu Z; Li Q
    Int J Nanomedicine; 2021; 16():471-480. PubMed ID: 33500617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome".
    Von Moos R; Cathomas R
    Eur J Dermatol; 2009; 19(3):264-5. PubMed ID: 19213658
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.